{
    "clinical_study": {
        "@rank": "93969", 
        "acronym": "EMDADER-TABI", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "There is no \"placebo\" treatment, and after randomization, patients were informed of their group assignments. The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life, adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment."
            }, 
            {
                "arm_group_label": "Pharmaceutical Care", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients and families will be provided with verbal and written information and education about mental health and bipolar disorder. Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by certain criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy (Depression- Mania Rating Scale, Clinical Global Assessment Scale,Quality of life, adherence to treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "This project aims, through pharmaceutical care in patients with Bipolar I Disorder, improve\n      compliance and adherence rate, associated with greater effectiveness and safety of drug\n      therapy to help achieve therapeutic goals, and finally to improving the quality of life of\n      patients."
        }, 
        "brief_title": "Effect of Pharmaceutical Care in Patients With Bipolar I Disorder (BD I)", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Actual"
        }, 
        "condition": "Bipolar Disorder", 
        "condition_browse": {
            "mesh_term": "Bipolar Disorder"
        }, 
        "detailed_description": {
            "textblock": "The objective of the present study was to assess the effectiveness of the Dader Method for\n      pharmaceutical care  in the reduction of the use of health care services and the increase in\n      the effectiveness and safety of treatment in patients with Bipolar I Disorder who are\n      discharged or referred for outpatient clinic St John of God-La Ceja. Primary objective: To\n      assess the effectiveness of the Dader method for pharmaceutical care on achieving in\n      reducing the number of hospital readmissions, in the increase of the effectiveness and\n      safety of treatment in patients discharged from the Clinic of Saint John of God -La Ceja -\n      Antioquia with bipolar disorder.\n\n      A randomized controlled trial. 200 patients will be randomized to group of control or\n      intervention.  Post-randomisation, patients will be required to attend the clinic routinely\n      every 3 months during one year. Every 3 months will be evaluated on the criteria of\n      effectiveness and safety of the treatment.  Intervention's group will be following through\n      pharmaceutical care. In the development of the study will be a record of the use of health\n      care services (rehospitalizations, care emergency and outpatient, additional to those\n      scheduled)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients diagnosed with Bipolar I Disorder\n\n          -  Have been discharged from the Clinic of Saint John of God -La Ceja-\n\n          -  Have been resulting from external consultation (outpatient) of the Clinic of Saint\n             John of God -La Ceja-\n\n          -  Male and female patients aged between 18 and 65 years\n\n          -  Living in Medellin or any of the following eastern municipalities in the department\n             of Antioquia.\n\n        Exclusion Criteria:\n\n          -  Patients with first episode of manic type, schizoaffective disorder, bipolar disorder\n             II, cyclothymia and other bipolar spectrum disorders, personality disorders that seem\n             bipolar disorder, sociopathic disorder.\n\n          -  Epilepsy\n\n          -  Patients unable to comply with the protocol requirements, including severe alcohol\n             and drug use.\n\n          -  Patients with diagnostic uncertainty.\n\n          -  Pregnancy or breastfeeding\n\n          -  Infection with the human immunodeficiency virus (HIV).\n\n          -  Chronic decompensate disease (no significant diseases): blood pressure values above\n             180/110 mmHg, total cholesterol above 300 mg / dL, low density cholesterol greater\n             than 160 mmHg, hemoglobin A1c greater than 9%, lower oxygen saturation 90%.\n\n          -  Mental retardation, presence of any cognitive impairment that prevents understands\n             and signs informed consent.\n\n          -  Refusal to sign informed consent (Consent must be obtained before any study-related\n             procedures are conducted).\n\n          -  Illiteracy.\n\n          -  Patients in electroconvulsive therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01750255", 
            "org_study_id": "EMDADER-TABI-20111108"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pharmaceutical Care", 
                "description": "Patients and their families will be provided with verbal and written information and education about mental health and bipolar disorder. Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy; Depression and Mania Rating Scale, Clinical Global Assessment Scale, Quality of life and adherence to treatment", 
                "intervention_name": "Pharmaceutical Care", 
                "intervention_type": "Other", 
                "other_name": [
                    "Pharmacotherapy follow-up", 
                    "Dader Method for pharmaceutical care"
                ]
            }, 
            {
                "arm_group_label": "Control", 
                "description": "The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life (Sf - 36 test), adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.", 
                "intervention_name": "Education", 
                "intervention_type": "Other", 
                "other_name": [
                    "Education", 
                    "Promotion of health", 
                    "Disease prevention", 
                    "Psycho-education"
                ]
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pharmaceutical care", 
            "Pharmacotherapy follow-up", 
            "Bipolar disorder", 
            "Pharmacy services"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "La Ceja", 
                    "country": "Colombia", 
                    "state": "Antioquia", 
                    "zip": "574"
                }, 
                "name": "Cl\u00ednica San Juan de Dios"
            }
        }, 
        "location_countries": {
            "country": "Colombia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Pharmaceutical Care in Patients With Bipolar I Disorder at St John of God Clinic. Randomized Trial.", 
        "overall_official": [
            {
                "affiliation": "Universidad de Antioquia", 
                "last_name": "Andrea Salazar, cDr.", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Universidad de Antioquia", 
                "last_name": "Pedro J Amariles, Dr.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Universidad de Antioquia", 
                "last_name": "Dora M Benjumea, Dr", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Cl\u00ednica San Juan de Dios", 
                "last_name": "Luis F Rodriguez, Dr", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Universidad de Antioquia", 
                "last_name": "Francisco J Gutierrez, Dr", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Colombia: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To reduce the use of health care services by quantifying the number of hospitalizations, emergency care and outpatient, in addition to those scheduled", 
            "measure": "Health care services use", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01750255"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universidad de Antioquia", 
            "investigator_full_name": "Pedro Amariles", 
            "investigator_title": "Pharmacy Doctor. Dean of Pharmacy Faculty.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To measure the quality of life will be used the Short Form-36 questionnaire. This questionnaire assesses vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health. Patient wellbeing [Time Frame: At 3, 6, 9 and 12 months]", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Adherence to treatment, in a direct way (through serum lithium levels, serum valproate levels and carbamazepine-serum level) and indirectly by means of the questionnaire of Morinsky-Green.[Time Frame: At 3, 6, 9 and 12 months]", 
                "measure": "Adherence to treatment", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The  Clinical  Global  Impressions  Scale  (CGI)  is an scale for use  in  assessing  global  illness  severity and  change  in  patients  with  bipolar  disorder. [Time Frame: At 3, 6, 9 and 12 months]", 
                "measure": "Clinical Global Impression for Bipolar Modified, CGI-BP-M.", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "To assess manic symptoms, will be used the Young Mania Rating Scale (YMRS). [Time Frame: At 3, 6, 9 and 12 months]", 
                "measure": "Mania", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "To assess depressive symptoms, will be used the the Hamilton Depression Rating Scale. [Time Frame: At 3, 6, 9 and 12 months]using hamilton depression scale", 
                "measure": "Depression", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Necessity problems of pharmacotherapy are related to the following two questions: 1) The patient has a health problem associated with not receiving a medication you need? 2) The patient has a health problem associated with getting a medicine that does not need. The safety of the pharmacotherapy will be measured by the safety profile of drugs and serum concentrations of drugs. The effectiveness of the pharmacotherapy will be measured by Hamilton Rating Scale for Depression, Clinical Global Impressions (CGI), Young Mania Rating Scale.", 
                "measure": "Necessity, effectiveness and security problems associated with pharmacotherapy", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Quantify the preventable causes of problems of effectiveness and safety of pharmacotherapy. Quantify the process problems like a drug availability problems, problems in prescribing, dispensing problems, administration and use, quality problem.[Time Frame: At 3, 6, 9 and 12 months]", 
                "measure": "Preventable causes of problems of effectiveness and safety of pharmacotherapy", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Universidad de Antioquia", 
        "sponsors": {
            "collaborator": {
                "agency": "Humax Pharmaceutical", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Universidad de Antioquia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}